Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 13/20 | 0.46 |
| ▸ | HTR1F | P30939 | 4/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4517381 | 0.88 | HTR1F (0.55) | HTR1FHTR1AHTR1B | |
| SCHEMBL13675116 | 0.83 | HTR1F (0.48) | WDR5HTR1FHTR1AHTR1B | |
| SCHEMBL4502359 | 0.82 | HTR1F (0.43) | HTR1FLCKMAPK14HTR1AHTR1B | |
| SCHEMBL4515858 | 0.82 | HTR1F (0.46) | WDR5HTR1FLCKMAPK14HTR1A | |
| SCHEMBL4498386 | 0.80 | RAB9A (0.55) | HTR1FHTR1A | |
| SCHEMBL4502990 | 0.79 | KCNQ3 (0.56) | HTR1FHTR1AHTR1B | |
| SCHEMBL4491851 | 0.77 | NPC1 (0.54) | SMN1; SMN2 | |
| SCHEMBL4515319 | 0.77 | SMN1; SMN2 (0.52) | SMN1; SMN2 | |
| SCHEMBL12020965 | 0.75 | LCK (0.49) | WDR5HTR1FLCKMAPK14 | |
| Hydrochloric Acid SCHEMBL1197922 | 0.74 | LCK (0.49) | WDR5HTR1FLCKMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1626958-B1 | (PIPERIDINYLOXY)PHENYL, (PIPERIDINYLOXY)PYRIDINYL, (PIPERIDINYLSULFANYL)PHENYL AND (PIPERIDINYLSULFANYL)PYRIDINYL COMPOUNDS AS 5-HT 1F AGONISTS | LILLY CO ELI (US) | 2012-06-27 | — | — | EP | disclosed |
| US-7608629-B2 | (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2009-10-27 | — | — | US | disclosed |
| US-20060211734-A1 | (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht1f agonists | ELILILLY AND COMPANY (US) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211734-A1 | (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht1f agonists | HTR1A, HTR1F, HTR5A | WDR5 4022/4885HTR1F 2/4885LCK 4200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.